IRLAB Therapeutics
5.11.2021 08:07:05 CET | ACCESS Newswire | Press release
GOTHENBURG, SE / ACCESSWIRE / November 5, 2021 / IRLAB Therapeutics (STO:IRLAB-A) (FRA:6IRA)
IRLAB Therapeutics AB (publ) will publish the interim report for the period January - September 2021 on Wednesday 10 November 2021 at 07:45 CET. A conference call will be held the same day starting at 10:30 CET, where CEO Nicholas Waters and CFO Viktor Siewertz will present the report. The presentation will be held in Swedish and will be followed by a Q&A session.
For those who wish to participate in the conference call, please dial:
SE + 46 850 558 373 or
UK + 44 333 300 9030
It is also possible to follow and listen to the presentation live on https://tv.streamfabriken.com/irlab-q3-2021
The presentation material will be available in Swedish and published in connection with the conference call on www.irlab.se , where the recorded version of the webcast will be available afterwards.
For more information
Åsa Hillsten, Head of IR & Corporate Communications
Mobile: +46 700 81 81 17
E-mail: asa.hillsten@irlab.se
About IRLAB
IRLAB is a Swedish research and development company that focuses on developing novel treatments in Parkinson's disease. The company's most advanced candidates, mesdopetam (IRL790) and pirepemat (IRL752), have completed Phase IIa studies and are designed to treat some of the most difficult symptoms related to Parkinson's disease: involuntary movements (PD-LIDs), psychosis (PDP) and symptoms linked to cognitive decline such as impaired balance and increased risk of falls (PD-Falls). Through the proprietary research platform, ISP (the Integrative Screening Process), IRLAB discovers and develops unique drug candidates for central nervous system (CNS)-related disorders where large and growing medical needs exist. In addition to the clinical candidates, the ISP platform has also generated several CNS programs that are now in preclinical phase. The project portfolio comprises a combination of the fully-funded mesdopetam program, run in collaboration with global partner Ipsen, as well as innovative in-house programs from preclinical to Phase IIb. IRLAB is listed on Nasdaq Stockholm Main Market. More information on www.irlab.se .
Attachments
Invitation to the presentation of IRLAB´s Interim report January - September 2021
SOURCE: IRLAB Therapeutics
View source version on accesswire.com:
https://www.accesswire.com/671344/Invitation-to-the-Presentation-of-IRLABs-Interim-Report-January-September-2021
To view this piece of content from www.accesswire.com, please give your consent at the top of this page.
About ACCESS Newswire
Subscribe to releases from ACCESS Newswire
Subscribe to all the latest releases from ACCESS Newswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from ACCESS Newswire
SK Tes Ireland Achieves ISO Certification Milestone and Recognized in National Digital Infrastructure Report4.6.2026 15:00:00 CEST | Press release
DUBLIN, IE / ACCESS Newswire / June 4, 2026 / SK tes, a global leader in sustainable technology lifecycle services, today announced that its Ireland facility has successfully passed audits for ISO 9001 (Quality Management), ISO 14001 (Environmental Management), ISO 45001 (Occupational Health & Safety), and ISO 27001 (Information Security Management), reinforcing its commitment to delivering consistent, high-quality, safe and sustainable services worldwide. These certifications are standard across SK tes' global network of facilities and form a core part of the company's operating model. As the newest site within this network, Ireland's certification reflects the structured commissioning process that ensures every SK tes location meets the same rigorous international standards - enabling clients to receive a consistent, secure, and compliant service experience, regardless of geography. In parallel, the Irish business has been recognized in the DII Economic Report 2026, published by Digi
Preservica takes AI for Digital Preservation to the next level with powerful new AI Editions4.6.2026 15:00:00 CEST | Press release
OXFORD, UK AND BOSTON, MA / ACCESS Newswire / June 4, 2026 / Preservica, a global leader in AI-powered Active Digital Preservation™, today announced the launch of its new AI Editions that combine human-centric AI tools with the built-in AI capacity to enable archival and records teams to quickly and safely transform their archives at scale. Developed in collaboration with the Preservica user community, the new AI Editions enable teams to process backlogs up to four times faster, meet privacy, accessibility, and FOI requirements, standardize metadata quality, accelerate content enrichment and discovery, and free time for higher-value work. With ample AI capacity included, teams can save significant time - cutting repetitive, manual work and quickly adding new value to their archives every month: Transcribe hundreds of hours of AV content or OCR thousands of scanned images or Identify PII in hundreds of thousands of documents or Standardize metadata across thousands of assets And more "S
Gedeon Richter Highlights Expanding Biosimilars Portfolio and Scientific Engagement at EULAR 20264.6.2026 14:45:00 CEST | Press release
LONDON, UK / ACCESS Newswire / June 4, 2026 / The Biotechnology Business Unit of Gedeon Richter Plc. (Richter) is present at this year's European Alliance of Associations for Rheumatology's (EULAR) European Congress of Rheumatology, underlining its role as a growing contributor to biologic therapies in Europe. The company also hosted a satellite symposium on the opening day, as part of its engagement with the rheumatology community. Richter's presence at EULAR reflects nearly two decades of focused investment following its strategic entry into biotechnology. Today, it operates a fully integrated biosimilars business with a European development and manufacturing network, including facilities in Budapest and Debrecen in Hungary, operations in Germany, and global partnerships supported by over 1,000 biotech professionals. As part of its scientific program, yesterday Richter hosted the symposium "Prevention, better than treatment - insights on inflammatory joint disease and osteoporosis" c
Media Invitation: Fields Medals and Cutting-Edge Math at ICM 2026 in Philadelphia2.6.2026 20:30:00 CEST | Press release
PHILADELPHIA, PA / ACCESS Newswire / June 2, 2026 / Members of the press are invited to the world's most prestigious mathematics conference, which will take place at the Pennsylvania Convention Center in Philadelphia from July 23 to July 30, 2026. Held every four years, the International Congress of Mathematicians (ICM) includes the announcement of the field's top prizes - including the Fields Medals - as well as top talks from leading mathematicians on cutting-edge developments in the field. Staff reporters and freelance journalists can register to attend the conference free of charge through June 22. Media registration includes access to a press conference with the Fields Medalists and other honorees following their announcement during the July 23 opening ceremony. A press room will also be available during the conference. Discounted hotel room rates are available to attendees. For more information, visit the ICM 2026 website or email icmpressinquiries@simonsfoundation.org. The confe
IXOPAY Launches Payments Intelligence and IXONav, an AI Payments Assistant Built to Unlock Real-Time Insights Across the Payments Journey2.6.2026 06:00:00 CEST | Press release
Company's intelligence layer combines AI-driven analytics with anomaly detection to improve merchant payments optimization, performance and revenue outcomes LEHI, UT / ACCESS Newswire / June 2, 2026 / IXOPAY, the performance layer powering global payments for the agentic era, today announced IXOPAY Payments Intelligence, a unified control center that transforms fragmented payment data into real-time, actionable insights. The company also launched IXONav, a new AI agentic navigator built to unlock key insights at every step in the payments journey. By combining AI-driven analytics, anomaly detection and LLM agents, the platform helps merchants uncover optimization opportunities, improve routing performance, increase authorization rates and reduce per-transaction costs. IXOPAY's no-code payments platform unifies payment orchestration, tokenization, and intelligence, and provides merchants with a configurable infrastructure to optimize their payments performance. The IXOPAY Payments Intel
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom